EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Impact of Clonal Hematopoiesis–Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial

Julieta Rodriguez iD, Capucine Baldini iD, Arnaud Bayle iD, Arnaud Pages iD, François Xavier Danlos iD, Damien Vasseur iD, Etienne Rouleau iD, Ludovic Lacroix iD, Beatriz Alonso de Castro iD, Vincent Goldschmidt iD, Lauren Seknazi, Antoine Hollebecque iD und 10 weitere

JCO Precision Oncology · 2024-05 · (8)

DOI: 10.1200/po.23.00631 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift JCO Precision Oncology, 2024-05. Verfasst von Julieta Rodriguez und 21 weiteren Autor:innen. Beteiligte Einrichtung: Drug Development Department, Gustave Roussy, Villejuif, France. Hauptthemen laut MEDLINE: Mutation, Neoplasms, Clonal Hematopoiesis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE With liquid biopsy's widespread adoption in oncology, an increased number of clonal hematopoiesis–associated mutations (CHm) have been identified in patients with solid tumors. However, its impact on patient outcomes remains unclear. This study aimed to analyze and describe CHm in a cohort of phase I patients. METHODS Retrospective data collection from medical records and molecular profiles (Foundation One Liquid CDx Assay) was performed before first study drug administration at the Drug Development Department of Gustave Roussy (France) within the STING trial (ClinicalTrials.gov identifier: NCT04932525 ). CHm prevalence was assessed using any and ≥1% variant allele frequency (VAF) in epigenetic modifier genes ( DNMT3A, TET2, and ASXL1). RESULTS From January 2021 to December 2022, 255 patients were enrolled in a phase I clinical trial. A total of 55% were male, with a median age of 62 years (24-86). Principal tumor locations were GI (27%) and genitourinary (21%). Overall, 104 patients (41%) had at least one CHm in liquid biopsy, with 55 patients (22%) having a VAF of ≥ 1%. The most frequent mutation was DNMT3A 73% at any VAF (n = 76) and 22% at 1% VAF (n = 23). Median progression-free survival (PFS) and overall survival were 3.8 months (m) for the CHm group versus 3.2 m for nonclonal hematopoiesis (CH; P = .08) and 18.26 m CHm versus 15.8 m non-CH ( P = .9), respectively. PFS increased in the CHm population treated with targeted therapy (hazard ratio, 0.6 [95% CI, 0.42 to 0.84]; P = .004). CONCLUSION CHm was commonly found in patients with solid tumors treated in phase I trials, with a prevalence of 41% in our cohort. The most frequently mutated gene was DNMT3A. The presence of CHm had no impact on the population of patients treated in the phase I trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationNeoplasmsClonal HematopoiesisHumansMaleMiddle AgedFemaleAgedAdultRetrospective StudiesAged, 80 and overYoung Adult

Autor:innen und Institutionen

  • Drug Development Department, Gustave Roussy, Villejuif, France.
  • Laboratory of Immunomonitoring in Oncology, Gustave Roussy, Villejuif, France.
  • Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France.
  • Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France.
  • A Coruña University Complex, Coruña, Spain.
  • Department of Hematology, Gustave Roussy, Villejuif, France.

ORCID-Profile: Julieta Rodriguez, Capucine Baldini, Arnaud Bayle, Arnaud Pages, François Xavier Danlos, Damien Vasseur, Etienne Rouleau, Ludovic Lacroix, Beatriz Alonso de Castro, Vincent Goldschmidt, Antoine Hollebecque, Jean-Marie Michot, Stephane Champiat, Aurelien Marabelle, Kaissa Ouali, Christophe Marzac, Jean-Baptiste Micol, Christophe Massard, Antoine Italiano

Zitieren

APA

Rodriguez, J., Baldini, C., Bayle, A., Pages, A., Danlos, F. X., Vasseur, D., Rouleau, E., Lacroix, L., Alonso de Castro, B., Goldschmidt, V., Seknazi, L., Hollebecque, A., Michot, J. M., Champiat, S., Marabelle, A., Ouali, K., Marzac, C., Ponce, S., Micol, J. B., …, & Italiano, A. (2024). Impact of Clonal Hematopoiesis–Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial. JCO Precision Oncology. https://doi.org/10.1200/po.23.00631

Vancouver

Rodriguez J, Baldini C, Bayle A, Pages A, Danlos FX, Vasseur D, et al. Impact of Clonal Hematopoiesis–Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial. JCO Precision Oncology. 2024. doi:10.1200/po.23.00631

BibTeX
@article{Rodriguez2024,
  author = {Rodriguez, Julieta and Baldini, Capucine and Bayle, Arnaud and Pages, Arnaud and Danlos, François Xavier and Vasseur, Damien and Rouleau, Etienne and Lacroix, Ludovic and Alonso de Castro, Beatriz and Goldschmidt, Vincent and Seknazi, Lauren and Hollebecque, Antoine and Michot, Jean-Marie and Champiat, Stephane and Marabelle, Aurelien and Ouali, Kaissa and Marzac, Christophe and Ponce, Santiago and Micol, Jean-Baptiste and Chaput, Nathalie and Massard, Christophe and Italiano, Antoine},
  title = {Impact of Clonal Hematopoiesis–Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial},
  journal = {JCO Precision Oncology},
  year = {2024},
  number = {8},
  doi = {10.1200/po.23.00631}
}
Kostenlos starten →